Lysergic Acid Diethylamide (LSD) in Palliative Care (LPC)

Inclusion Criteria: Age ≥ 25 years. End-stage fatal disease of any cause with a life expectancy ≥ 12 weeks and ≤ 2 years Sufficient understanding of the study procedures and risks associated with the study. Participants must be willing to adhere to the study procedures and sign the consent form. Participants must be willing not to drive a traffic vehicle or to operate machines within 24 h after LSD administration. Participants must complete an actual "Emergency Medical Directive" Exclusion Criteria: Life expectancy < 12 weeks Known hypersensitivity to LSD Requiring ongoing concomitant therapy with a psychoactive prescription drug which might interfere with the study drug, and unable or unwilling to comply with the washout period. Current use of a potent drug CYP2D6 inhibitor Women who are pregnant or nursing or intend to become pregnant during the course of the study. Somatic disorders including CNS involvement of cancer, epilepsy with a history of seizures, history of delirium, end-stage heart failure (NYHA IV), untreated hypertension or insufficiently treated hypertension, angina pectoris, severe liver disease or severely impaired renal function, or other that in the judgement of the investigators pose too great potential for side effects. Inability to follow the procedures of the study, e.g., due to language problems, psychological disorders, dementia, etc. of the participant. Participation in another study with an investigational drug within the 30 days preceding and during the present study concomitant diagnosis of past or present psychotic disorder concomitant diagnosis of past or present bipolar disorder substance use disorder (within the last 2 months, except nicotine, opioids used for analgesia, and benzodiazepine treatment for anxiety). Weight < 45 kg Suicidal ideation with active intent or plan to act on suicidal thoughts as assessed by the treating investigator.